LMR Partners LLP Buys 743 Shares of STAAR Surgical (NASDAQ:STAA)

LMR Partners LLP grew its stake in STAAR Surgical (NASDAQ:STAA) by 2.2% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 34,712 shares of the medical instruments supplier’s stock after buying an additional 743 shares during the period. LMR Partners LLP’s holdings in STAAR Surgical were worth $1,290,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Arcadia Investment Management Corp MI purchased a new stake in STAAR Surgical in the 3rd quarter worth approximately $37,000. Covestor Ltd boosted its position in shares of STAAR Surgical by 38.9% in the first quarter. Covestor Ltd now owns 2,690 shares of the medical instruments supplier’s stock worth $103,000 after purchasing an additional 754 shares during the period. Quest Partners LLC purchased a new stake in shares of STAAR Surgical in the third quarter worth $128,000. Canada Pension Plan Investment Board bought a new stake in shares of STAAR Surgical during the 2nd quarter valued at $129,000. Finally, Van ECK Associates Corp lifted its stake in shares of STAAR Surgical by 12.7% during the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after buying an additional 393 shares in the last quarter. Institutional investors own 96.70% of the company’s stock.

Analysts Set New Price Targets

STAA has been the topic of a number of recent analyst reports. Stifel Nicolaus decreased their price target on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, August 26th. Canaccord Genuity Group lowered their price target on STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $43.33.

STAAR Surgical Stock Performance

NASDAQ STAA opened at $26.14 on Wednesday. The stock has a 50 day moving average price of $31.14 and a 200-day moving average price of $36.96. STAAR Surgical has a one year low of $26.02 and a one year high of $52.68. The company has a market capitalization of $1.29 billion, a P/E ratio of 59.41 and a beta of 0.61.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.